Skip to content
Screener

Amylyx Pharmaceuticals, Inc. AMLX Q1 2026 earnings

Reported May 7, 2026 · Before market open

EPS-$0.37Miss by $0.03
EPS estimate-$0.34

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$59.4K
EPS estimate-$0.38

Financials

Q1 2026

Income statement

See full
Operating income-$43.8M-15.8%
Net income-$41.3M-15.0%
EPS (diluted)-$0.37+11.9%

Balance sheet

See full
Cash & equivalents$229.1M+283%
Total debt$5.6M+307%
Total equity$273.2M+35.6%
Total assets$293.6M+33.7%

Cash flow

See full
Operating cash flow-$36.9M+7.4%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.54B+390%
Enterprise value$1.31B+414%

Returns & leverage

See full
Return on equity-63.3%-12.2pp
Debt / equity0×0.0×
Current ratio17.9×+5.8×

FAQ

When did Amylyx Pharmaceuticals, Inc. report Q1 2026 earnings?
Amylyx Pharmaceuticals, Inc. (AMLX) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Amylyx Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Amylyx Pharmaceuticals, Inc. reported eps of $-0.37 for Q1 2026.
Did Amylyx Pharmaceuticals, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.34 by $0.03.
How did Amylyx Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 11.9% from $-0.42.
Where can I find Amylyx Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210286) and the 10-Q periodic report (0001193125-26-210292) directly on SEC EDGAR. The filing index links above go to sec.gov.